Peláez Pau, Damiá Elena, Torres-Torrillas Marta, Chicharro Deborah, Cuervo Belén, Miguel Laura, Del Romero Ayla, Carrillo Jose Maria, Sopena Joaquín J, Rubio Mónica
Bioregenerative Medicine and Applied Surgery Research Group, Department of Animal Medicine and Surgery, CEU Cardenal Herrera University, CEU Universities, C/Tirant lo Blanc, 7, Alfara del Patriarca, 46115 Valencia, Spain.
Garcia Cugat Foundation CEU-UCH Chair of Medicine and Regenerative Surgery, 08006 Barcelona, Spain.
Biomedicines. 2021 Nov 19;9(11):1726. doi: 10.3390/biomedicines9111726.
Osteoarthritis (OA) is the most common articular disease in adults and has a current prevalence of 12% in the population over 65 years old. This chronic disease causes damage to articular cartilage and synovial joints, causing pain and leading to a negative impact on patients' function, decreasing quality of life. There are many limitations regarding OA conventional therapies-pharmacological therapy can cause gastrointestinal, renal, and cardiac adverse effects, and some of them could even be a threat to life. On the other hand, surgical options, such as microfracture, have been used for the last 20 years, but hyaline cartilage has a limited regeneration capacity. In recent years, the interest in new therapies, such as cell-based and cell-free therapies, has been considerably increasing. The purpose of this review is to describe and compare bioregenerative therapies' efficacy for OA, with particular emphasis on the use of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). In OA, these therapies might be an alternative and less invasive treatment than surgery, and a more effective option than conventional therapies.
骨关节炎（OA）是成年人中最常见的关节疾病，在65岁以上人群中的当前患病率为12%。这种慢性疾病会损害关节软骨和滑膜关节，引起疼痛，并对患者的功能产生负面影响，降低生活质量。骨关节炎的传统疗法存在许多局限性——药物治疗会引起胃肠道、肾脏和心脏的不良反应，其中一些甚至可能危及生命。另一方面，诸如微骨折等手术选择在过去20年中一直在使用，但透明软骨的再生能力有限。近年来，人们对基于细胞和无细胞疗法等新疗法的兴趣大幅增加。本综述的目的是描述和比较生物再生疗法对骨关节炎的疗效，特别强调间充质干细胞（MSCs）和富血小板血浆（PRP）的使用。在骨关节炎中，这些疗法可能是一种比手术侵入性更小的替代治疗方法，并且比传统疗法更有效。
